91 results
8-K
EX-99.1
EDIT
Editas Medicine, Inc.
28 Feb 24
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
7:06am
for the same period in 2022. The increase is primarily attributable to sublicense payments made in connection with the Vertex license agreement offset … . The increase is primarily attributable to sublicense payments made in connection with the Vertex license agreement, partially offset by decreased external
8-K
EX-10.1
4aegj59v
22 Nov 23
Departure of Directors or Certain Officers
4:10pm
424B5
hlff7ro
15 Jun 23
Prospectus supplement for primary offering
4:22pm
424B5
giv35d 0fv
15 Jun 23
Prospectus supplement for primary offering
4:22pm
424B5
rcxo5l lck3
14 Jun 23
Prospectus supplement for primary offering
5:20pm
8-K
EX-99.1
ns09yxenwt7uhq1a8oi
5 May 23
Editas Medicine Announces First Quarter 2023 Results and Business Updates
7:16am
8-K
EX-99.1
pmj5clnt
4 May 22
Editas Medicine Announces First Quarter 2022 Results and Business Updates
7:00am